Tachyon Ventures

Tachyon Ventures is a venture capital firm specializing in early-stage investments in biotechnology companies, focusing on innovative therapeutics and medical technologies. They provide early-stage smart capital to entrepreneurs pushing the boundaries at the forefront of medicine, biotech, and bioengineering. Supported by a network of engaged, deeply knowledgeable scientists at world-leading research institutions, Tachyon Ventures emphasizes scientific risk-arbitrage, aiming to price scientific risk earlier than others and maximize upside potential by investing early in disruptive platforms. They mitigate risk by focusing on world-class research with protected intellectual property.

Their investment strategy centers on identifying good science early and assessing its potential at different stages of development. Tachyon Ventures is committed to supporting scientific teams pursuing ambitious goals and transformative technologies at the forefront of medicine, biotech, and bioengineering. They back teams with world-leading published research, recognized as leaders in their fields and at the forefront of their research areas, and invest in companies with protected intellectual property developed by or in collaboration with their scientific co-founders.

Tachyon Ventures has a diverse portfolio of companies, including Mammoth Biosciences, Enclear Therapies, Totient, DTx Pharma, and Scipher Medicine. Their impact is evident in the over $1 billion raised by their portfolio companies after their investment, with two companies reaching pre-IPO stages and three achieving exits. This track record underscores their effective approach to fostering innovation and growth in the biotechnology sector.